Muscle loss from GLP-1
Both oral and subcutaneous doses of this medication may cause abdominal discomfort, such as bloating, gas, cramping, or sharp pains
Best Use Case Orforglipron may be ideal for individuals seeking a non-injectable option with solid metabolic improvements
In a 2026 editorial commentary published in Cureus , citing findings from the STEP 4 and SURMOUNT 4 clinical trials, the author described how stopping GLP-1 medication may unmask counter-regulatory hunger signals including potential changes in ghrelin activity that had been suppressed while the medication was active (Quimbayo-Cifuentes, 2026)
We take into account both diabetes management and weight regulation to create a tailored treatment plan that aligns with your health goals
Matsuo K, Yabuki Y, Fukunaga K (2020) 5-aminolevulinic acid inhibits oxidative stress and ameliorates autistic-like behaviors in prenatal valproic acid-exposed rats